Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results